Douglass Winthrop Advisors LLC Trims Stock Position in Eli Lilly and Company (NYSE:LLY)

Douglass Winthrop Advisors LLC trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 1.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,881 shares of the company’s stock after selling 105 shares during the period. Douglass Winthrop Advisors LLC’s holdings in Eli Lilly and Company were worth $7,868,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Fisher Asset Management LLC grew its holdings in shares of Eli Lilly and Company by 3.5% during the third quarter. Fisher Asset Management LLC now owns 5,058,101 shares of the company’s stock worth $4,481,175,000 after purchasing an additional 169,391 shares during the last quarter. Daiwa Securities Group Inc. grew its stake in Eli Lilly and Company by 19.4% during the 3rd quarter. Daiwa Securities Group Inc. now owns 135,365 shares of the company’s stock worth $119,925,000 after buying an additional 21,975 shares during the last quarter. Hartford Funds Management Co LLC grew its stake in Eli Lilly and Company by 4.0% during the 3rd quarter. Hartford Funds Management Co LLC now owns 1,418 shares of the company’s stock worth $1,256,000 after buying an additional 55 shares during the last quarter. Pekin Hardy Strauss Inc. increased its position in Eli Lilly and Company by 13.3% during the third quarter. Pekin Hardy Strauss Inc. now owns 1,536 shares of the company’s stock worth $1,361,000 after buying an additional 180 shares during the period. Finally, Summit Trail Advisors LLC lifted its stake in Eli Lilly and Company by 10.5% in the third quarter. Summit Trail Advisors LLC now owns 7,549 shares of the company’s stock valued at $6,688,000 after buying an additional 718 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 0.3 %

Shares of Eli Lilly and Company stock opened at $748.01 on Monday. The company has a 50-day moving average of $865.01 and a two-hundred day moving average of $870.32. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The stock has a market cap of $710.10 billion, a PE ratio of 80.87, a price-to-earnings-growth ratio of 2.83 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business’s revenue for the quarter was up 20.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 earnings per share. On average, research analysts anticipate that Eli Lilly and Company will post 13.2 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.70%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on LLY. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Barclays lowered their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Bank of America dropped their price target on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. Finally, BMO Capital Markets lifted their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,007.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.